+ Contact

Neil Hayes
Commercial Manager
01392 723180

This computational biomarker can help with the rapid diagnosis of epilepsy

Assessing susceptibility to Epilepsy

This 'seizure susceptibility' measure can serve as both a biomarker of idiopathic generalised epilepsy and also as a means of gaining a statistical measure of the efficacy of any administered anti-epilepsy drug (AED).

The method gives a statistical probability of seizure, based on a computational model of the results of EEG analysis.

Key benefits

  • Can provide an objective measure for diagnosing epilepsy. Current diagnosis is subjective to clinician’s expertise, witness account and subjective interpretation of EEG, MRI readouts.
  • Diagnosis can be rapid. Current practice leads to a delay in providing AED medication to patients with epilepsy.
  • Reduction of falsely diagnosed patients will lead to fewer people taking medication unnecessarily.


  • Diagnosis of epileptic seizures in patients more rapidly and accurately than present.
  • Prognostic tool to determine the efficacy of a particular AED over a much more rapid timescale than current methods which trial and error test.

IP status

A PCT patent application has been submitted PCT/GB2013/051485

Commercial opportunity

The University is keen to discuss potential partnerships with a view to collaborations to develop a commercially available product